Return to the Faculty List
John W. Newcomer, MD
Current
Position
Gregory B. Couch Professor of Psychiatry
University Roles
Professor of Psychology and Medicine;
Director, Clinical Trials Unit, Institute of Clinical & Translational Sciences (ICTS)
Director, Regulatory Support Center, ICTS
Medical Director, Center for Clinical Studies
Education and Training
A.B., Magna Cum Laude, Philosophy of Science, Brown University, Providence, Rhode Island, 1981
Medical Degree: Wayne State University School of Medicine, Detroit Medical Center, Detroit, Michigan, 1985
Residency: Psychiatry, Stanford University School of Medicine, Palo Alto, California, 1989
Fellowship: Psychiatry Research, Stanford University School of Medicine, Stanford, California, 1990
Major Awards
Gregory B. Couch Professorship in Psychiatry
Distinguished Fellow, American Psychiatric Association, 2006
Independent Scientist Award (MH01045), National Institute of Mental Health Award, 1997-2002
Outstanding Scientist/Researcher Award, National Alliance for the Mentally Ill, 1999
Exemplary Psychiatrist Award, National Alliance for the Mentally Ill, 1999
Young Investigator Award, International Society of Psychoneuroendocrinology, 1998
Scientist Development Award (MH01045), National Institute of Mental Health Award, 1992-1997
Young Investigator Award, International Congress on Schizophrenia Research, 1993
Areas of Clinical Interest
Psychopharmacology, general medical health and cardiometabolic risk in individuals with mental illness; treatment of mental disorders
Areas of Research Interests
Cardiometabolic risk in individuals with mental disorders; glucose and lipid metabolism; schizophrenia, general clinical research, geriatric and child psychiatry, neuropsychopharmacology, psychoneuroendocrinology, diabetes, adult outpatient psychiatry, clinical psychopharmacology, psychiatric disorders of the nervous system, memory and aging, neurochemical regulation of memory performance in humans, therapies for neuropsychiatric disorders, particularly psychotic disorders.
Key Publications
Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD (2008 Jul 1). A Multicenter, Randomized, Double-Blind Study of the Effects of Aripiprazole in Overweight Subjects With Schizophrenia or Schizoaffective Disorder Switched From Olanzapine. J Clin Psychiatry. e1-e11. Full Article ->
Newcomer JW, Hennekens CH (2007 Oct 17). Severe mental illness and risk of cardiovascular disease. JAMA. 298(15): 1794-1796. Full Article ->
Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine and risperidone. J Clin Psychiatry 2009, 70(4):487-499. Full Article ->
Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW: Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009, 166(3):345-353. Full Article ->
Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B: Metabolic Screening after the ADA’s Consensus Statement on Antipsychotic Drugs and Diabetes. Diabetes Care, 2009, in press. Full Article ->
Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE: Obesity among those with mental disorders: A National Institute of Mental Health Meeting Report. Amer J Prev Med 2009, 36(4):341-350. Full Article ->
Funded Research Projects
NIMH (PI): Metabolic Effects of Antipsychotics in Children
NIMH (Key Personnel): Improving Depression Treatment Outcomes with an Insulin-Sensitizing Agent
NIMH (Key Personnel): Incomplete Response in Late Life Depression: Getting to Remission
NARSAD (Sponsor): Biomarkers of Cardiometabolic Risk in Children Treated with Antipsychotics: A Reliminary Study of Direct, Noninvasive Measures
NARSAD (Sponsor): Direct Noninvasive Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
NARSAD (Sponsor): Effects of Behavioral Therapy on Adiposity in Antipsychotic-Treated Hispanic Patients with Major Mental Illness: A Washington Heights Community Service Study